Diagnosing and classifying acute myeloid leukemia using bone marrow specimens
Providing guidance for clinical management of patients
Confirming a gene fusion detected by next-generation sequencing
Tracking response to therapy
Test Id | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
JAMMP | Probe, Each Additional (JAMLM) | No, (Bill Only) | No |
A charge and CPT code is applied for each probe set hybridized, analyzed and reported.
The following fluorescence in situ hybridization (FISH) probes are orderable individually or as a set:
Dual color dual fusion probes for PML::RARA fusion
Dual color dual fusion probes for RUNX1T1::RUNX1 fusion
Dual color break-apart probes for CBFB::MYH11 fusion
Dual color break-apart probes for KMT2A rearrangement
Dual color dual fusion probes for DEK::NUP214 fusion
Tri- color dual fusion probes for BCR::ABL1 fusion
Dual color break-apart probes for MECOM rearrangement
Fluorescence In Situ Hybridization (FISH)
CEBPA
CBFB/MYH11
CBF::MYH11
MECOM
KMT2A
NPM1
NUP98
PML/RARA
PML::ARA
DEK/NUP214
DEK::NUP214
RUNX1T1/RUNX1
RUNX1T1::RUNX1
BCR/ABL
BCR::ABL
A charge and CPT code is applied for each probe set hybridized, analyzed and reported.
The following fluorescence in situ hybridization (FISH) probes are orderable individually or as a set:
Dual color dual fusion probes for PML::RARA fusion
Dual color dual fusion probes for RUNX1T1::RUNX1 fusion
Dual color break-apart probes for CBFB::MYH11 fusion
Dual color break-apart probes for KMT2A rearrangement
Dual color dual fusion probes for DEK::NUP214 fusion
Tri- color dual fusion probes for BCR::ABL1 fusion
Dual color break-apart probes for MECOM rearrangement
Bone Marrow
Specimen must arrive within 7 days of collection.
The following information is required:
1. Pertinent clinical history
2. Clinical or morphologic suspicion
3. Date of collection
4. Specimen source
Container/Tube: Green top (Sodium Heparin) or yellow top (ACD solution B)
Specimen Volume: 2 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.
1 mL
Gross hemolysis | Reject |
Moderately to severely clotted | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Bone Marrow | Ambient (preferred) | 7 days | |
Refrigerated | 7 days |
Diagnosing and classifying acute myeloid leukemia using bone marrow specimens
Providing guidance for clinical management of patients
Confirming a gene fusion detected by next-generation sequencing
Tracking response to therapy
A charge and CPT code is applied for each probe set hybridized, analyzed and reported.
The following fluorescence in situ hybridization (FISH) probes are orderable individually or as a set:
Dual color dual fusion probes for PML::RARA fusion
Dual color dual fusion probes for RUNX1T1::RUNX1 fusion
Dual color break-apart probes for CBFB::MYH11 fusion
Dual color break-apart probes for KMT2A rearrangement
Dual color dual fusion probes for DEK::NUP214 fusion
Tri- color dual fusion probes for BCR::ABL1 fusion
Dual color break-apart probes for MECOM rearrangement
Acute myeloid leukemia (AML) has been defined by genetic abnormalities and differentiation in the 5th edition of World Health Organization classification of hematolymphoid tumors.(1)
The subtypes of AML defined by genetic abnormalities include:
Acute promyelocytic leukemia with PML::RARA fusion
AML with RUNX1::RUNXT1 fusion
AML with CBFB::MYH11 fusion
AML with DEK::NUP214 fusion
AML with RBM15::MRTFA fusion
AML with BCR::ABL1 fusion
AML with KMT2A rearrangement
AML with MECOM rearrangement
AML with NUP98 rearrangement
AML with NPM1 mutation
AML with CEBPA mutation
AML myelodysplasia-related
AML with other defined genetic alterations
Fluorescence in situ hybridization (FISH) testing detects specific gene fusions associated with AML.
FISH testing will not detect gene variants associated with AML.
RBM15::MRTFA fusion and NUP98 rearrangement will not be detected in this FISH test. These two abnormalities are rare and can be detected by next-generation sequencing. FISH testing for these two abnormalities may be added to this test at later date.
A separate FISH panel will be performed to detect the defining genetic abnormalities for myelodysplasia-related AML.
An interpretive report will be provided.
Detection of a specific fusion or a rearrangement confirms a clinical diagnosis of acute myeloid leukemia (AML) and defines an AML classification. Absence of a specific gene fusion or rearrangement will not rule out presence of AML.
Fluorescence in situ hybridization (FISH) results should be correlated with clinical and pathologic information for diagnosis and treatment.
FISH testing is not a substitute for conventional chromosome studies because the latter detects many other chromosome abnormalities associated with acute myeloid leukemia and other hematological disorders.
Bone marrow is the preferred specimen type. If bone marrow is not available, a blood specimen may be used if there are malignant cells in the blood specimen (as verified by a hematopathologist); see JAMLB / Acute Myeloid Leukemia (AML), FISH, Blood.
Each probe was independently tested and verified on unstimulated peripheral blood specimens. Normal cutoffs were calculated based on the results of 22 normal specimens. Each probe set was evaluated to confirm the probe set detected the abnormality it was designed to detect.
1. Khoury JD, Solary E, Abla O et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719. doi:10.1038/s41375-022-01613-1
2. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447
Fluorescence in situ hybridization is performed using commercially available probes, including the dual/tri-color dual fusion DNA probes for PML::RARA, RUNX1T1::RUNX1, DEK::NUP214, and BCR::ABL1 fusion and break-apart probes for CBFB, KTM2A, and MECOM rearrangement. Two-hundred interphase nuclei are analyzed for each probe set by 2 laboratory technologists, 100 per technologist. All results are interpreted as positive or negative based on the cut-off established by the validation in this lab and reported using an International System for Human Cytogenetic Nomenclature.(Unpublished Mayo method)
Monday through Friday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
88377 (if 1 probe set)
88377 x 2 (if 2 probe sets)
88377 x 3 (if 3 probe sets)
88377 x 4 (if 4 probe sets)
88377 x 5 (if 5 probe sets)
88377 x 6 (if 6 probe sets)
88377 x 7 (if 7 probe sets)
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
JAMLM | AML FISH, Bone Marrow | 102103-9 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
620195 | Result Summary | 50397-9 |
620196 | Interpretation | 59465-5 |
620197 | Result | 62356-1 |
620198 | Reason For Referral | 42349-1 |
620341 | Probes Requested | 62370-2 |
620199 | Specimen | 31208-2 |
620200 | Source | 31208-2 |
620201 | Method | 85069-3 |
620202 | Additional Information | 48767-8 |
620203 | Disclaimer | 62364-5 |
620204 | Released By | 18771-6 |